AAP
CADL icon

Arax Advisory Partners’s Candel Therapeutics CADL Stock Holding History

Arax Advisory Partners’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17K Buy
+211
New +$1.59K ﹤0.01% 4798
2025
Q4 		– Sell
-54
Closed -$275 – 4142
2025
Q3 		$275 Buy
+54
New +$312 ﹤0.01% 3425

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arax Advisory Partners's CADL Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Candel Therapeutics (CADL) in Q2 2026: 211 shares worth $2.17K. The stake represents ﹤0.01% of the portfolio and ranks #4798 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in CADL as recently as Q3 2025.

Arax Advisory Partners first reported a position in CADL in Q3 2025 and has held it in 2 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Arax Advisory Partners held 211 shares of Candel Therapeutics worth $2.17K as of Q2 2026.
  • Candel Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4798 holding.
  • Arax Advisory Partners first reported a position in Candel Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.